US2903396A - Therapeutic compositions and method for treating parkinsonism - Google Patents

Therapeutic compositions and method for treating parkinsonism Download PDF

Info

Publication number
US2903396A
US2903396A US657708A US65770857A US2903396A US 2903396 A US2903396 A US 2903396A US 657708 A US657708 A US 657708A US 65770857 A US65770857 A US 65770857A US 2903396 A US2903396 A US 2903396A
Authority
US
United States
Prior art keywords
alcohol
ethyl
mixture
ethyl alcohol
thickening agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US657708A
Inventor
Saunders John Clarke
Lazarus Jack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CIBA PHARM PROD Inc
CIBA PHARMACEUTICAL PRODUCTS Inc
Original Assignee
CIBA PHARM PROD Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CIBA PHARM PROD Inc filed Critical CIBA PHARM PROD Inc
Priority to US657708A priority Critical patent/US2903396A/en
Application granted granted Critical
Publication of US2903396A publication Critical patent/US2903396A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/90—In vivo diagnostic or in vivo test agent which contains an additional ingredient to reduce the toxicity or side effects of the active ingredient

Definitions

  • Paralysis agitans commonly known as Parkinsons disease
  • Parkinsons disease is a degenerative process of that part of the brain known as the basal ganglia.
  • the cause of the degeneration is unknown but the symptoms are readily detectable.
  • a perculiar tremor and rigidity of either or both of the upper extremities Although slow in onset, the tremors gradually become more and more noticeable, particularly when an attempt is made to write. As the disease progresses, the tremor and rigidity may become so profound that they completely incapacitate the afflicted individual.
  • Parkinsonism is, to date, an incurable disease, it is common practice to give at least symptomatic relief. This is usually done by means of drug therapy, surgery or a combination of both. Atropine, scopolamine, stramonium, trihexyphenidyl hydrochloride and similar palliatives have been used in the past but patients rapidly develop tolerances to these drugs and staggering of medications often becomes necessary. Since the disease is chronic, a point is eventually reached where drug administration becomes completely ineifective; Procaine injections are sometimes successful, but they too are temporary.
  • the target area for the relief of symptoms of Parkinsonism appears to be the globus pallidus, which is a small portion of the basal ganglia and which, when diseased, is contributory to the development of Parkinsonian tremor and rigidity.
  • the destruction of this neurological center if effected properly without acc mpanying obliteration of immediately adjacent vital areas, has been thought of as the best means for affording symptomatic relief.
  • One of the methods heretofore employed for this purpose has been to inject a quantity of dehydrated alcohol directly into the globus pallidus preceded by an injection of procaine to confirm the location of the needle in the desired position.
  • procaine an injection of procaine
  • compositions comprising a mixture of ethyl alcohol and an alcohol-soluble thickening agent is useful for chemosurgical removal of Parkinsonian symptoms.
  • the novel composition completely overcomes the disadvantages'of dehydrated alcohol per se. When injected properly into the globus .pallidus it becomes localized in this area resulting in the formation of a permanent, discrete lesion, which abolishes Parkinsonian tremors and rigidity without'loss of'motorpowers'.
  • an alcohol-soluble thickening agent to ethyl alcohol not only localizes the effect of the alcohol after injection, thus insuring proper concentration in the globus pallidus, but also prevents the dissemination of the alcohol into the internal capsule, thus precluding fatal results.
  • alcohol-soluble thickening agents may be used in accordance with this invention, the only precaution being that the thickcners must be non-toxic and suitable for parenteral administration.
  • various' celluloses such as ethyl cellulose, cellulose acetate phthalate, etc.; the higher fatty alcohols such as cetyl alcohol, stearyl alcohol; palmityl alcohol, and their corresponding acids; alcohol-soluble silicone resins, synthetic resins, gums, etc.
  • Castor oil which is one of the few fixed alcohol-soluble oils, can also be used.
  • the amount of alcohol-soluble thickening agent to be combined with the ethyl alcohol is critical not only from the physiological point of-view, i.e. compatibility with tissue, but also because ofthe practical problems involved. Since an 18-gauge needle is usually employed for administration, the viscosity of the composition must be such as to permit easy flow through the bore of a needle of such diameter. Thus, if too much thickening agent is added to the alcohol, the mixture will not pass through the needle. If, on the other hand, an inadequate amount is added to the alcohol, the spread of the alcohol will not be impeded and attendant serious results may occur. We have found that a solution containing from about 0.5% to about 50% of thickening agent is suitable, the exact amount used depending largely upon the kind of thickener being employed.
  • ethyl cellulose a preferred range is from about 5% to about 20%. Optimally, we have found that'a concentration of from about 8% to about 10% ethyl cellulose affords the most desirable results. If cetyl alcohol is used as the thickening agent, it may be added in an amount varying from about 20% to about 40%. A preferred range is from about 25% to about 35%.
  • compositions of this invention may be used for the relief of symptoms in a wide variety of hyperkinetic diseases such as psychomotor equivalents, Huntingtons chorea, athetosis, cerebral palsy, etc. and it is intended that the use or uses in the treatment of these diseases be included within the scope of'this invention.
  • hyperkinetic diseases such as psychomotor equivalents, Huntingtons chorea, athetosis, cerebral palsy, etc. and it is intended that the use or uses in the treatment of these diseases be included within the scope of'this invention.
  • the exact dose ofthe composition to be administered will vary somewhat from patient to patient depending upon the condition of the patient, the extent of the disease being treated and the desires of the administering surgeon. In general, a dose within the range of 0.4 ml. to 1.0 ml. may be administered directly into the globus pallidus. In practice it has been found that an. initial dose of about 0.4 ml. followed by a second dose within the above range about three days postoperatively is adequate for removing symptoms of Parkinsonian tremor and rigidity.
  • a small quantity of X-ray contrast material for example an alcohol-soluble, iodinated, organic radiopaque substance suitable for parenteral administration, may be added to the composition for the purpose of enabling the surgeon to determine not only the exact location, but also the extent of the discrete lesion.
  • a wide variety of substances may be used, representative examples of which are the following: 3-acetamido-2,4,6-triiodobenzoic acid; ethyl iodophenylundecylate; ethyl ester of the iodinated mixture of oleic and linoleic acids of poppy seed oil (available under the trademark Ethiodol); ethyl diiodobrassidate; N,Nadipyl-bis-(3-amino-2,4,6-triiodo) benzoic acid; 3,5-diiodo-4-pyridone-N-acetic acid; fi-(3-amino- 2,4,6-triiodophenyl)-a-ethylpropionic acid; and l-methyl- 3,5-diiodo-4-pyridone 2,6-dicarbocyelic acid.
  • the method of preparation of the compositions is not critical. It involves admixing the desired quantities of alcohol and thickening agent thoroughly to insure complete solution (with heat if necessary) and sterilizing the resulting mixture at the proper temperature and pressure.
  • Example 1 Ethyl cellulose, 20 cps. viscosity 8.0 Ethyl alcohol, 95% qs 100.0
  • Example 3 Ethyl cellulose, 20 cps. viscosity 10.0 Ethyl iodophenylundecylate 10.0
  • a therapeutic composition comprising a mixture of ethyl alcohol, from about 0.5% to about 50% of an alcohol-thickening agent and a radiopaque substance.
  • a therapeutic composition comprising a mixture of ethyl alcohol, from about 0.5% to about 50% of an alcohol thickening agent and from about 1% to about 20% of a radiopaque substance.
  • a therapeutic composition comprising essentially a mixture of ethyl alcohol and from about 0.5% to about 50% cetyl alcohol.
  • a therapeutic composition comprising essentially a mixture of ethyl alcohol and from about 0.5% to about 50% stearyl alcohol.
  • a therapeutic composition comprising essentially a mixture of ethyl alcohol and from about 0.5% to about 50% stearic acid.
  • a therapeutic composition comprising essentially a mixture of ethyl alcohol and from about 0.5 to about 50% cellulose acetate phthalate.
  • a therapeutic composition comprising essentially a mixture of ethyl alcohol and from about 5% to about 20% ethyl cellulose.
  • a therapeutic composition comprising essentially a mixture of ethyl alcohol and irom about 8% to about 10% ethyl cellulose.
  • a therapeutic composition comprising a mixture of ethyl alcohol, from about 0.5% to about 50% of an alcohol-thickening agent and from about 1% to about 20% ethyl iodophenylundecylate.
  • a therapeutic composition comprising a mixture of ethyl alcohol, from about 0.5% to about 50% ethyl cellulose and from about 1% to about 20% ethyl idophenylundecylate.
  • a therapeutic composition comprising a mixture of ethyl alcohol, from about 0.5 to about 50% of an alcohol-thickening agent and from about 1% to about 20% ethyl diiodobrassidate.
  • a therapeutic composition comprising a mixture of ethyl alcohol, from about 0.5 to about 50% of an alcohol-thickening agent and from about 1% to about 20% of the ethyl ester iodinated mixture of oleic and linoleic acids of poppy seed oil.
  • a therapeutic composition comprising a mixture of ethyl alcohol, from about 0.5% to about 50% of an alcohol-thickening agent and from about 1% to about 20% N,N-adipyl-bis-(3-amino-2,4,6-triiodo) benzoic acid.
  • a therapeutic composition comprising a mixture of ethyl alcohol, from about 0.5 to about 50% of an alcohol-thickening agent and from about 1% to about 20% 3,5-diiodo-4-pyridone-N-acetic acid.
  • a method for the treatment of Parkinsonism which comprises injecting a mixture of ethyl alcohol and an alcohol-thickening agent into the globus pallidus.
  • a method for the treatment of hyperkinetic dis cases which comprises injecting into the body a mixture of ethyl alcohol, an alcohol-thickening agent and a radiopaque substance.
  • a method for the treatment of Parkinsonism which comprise injecting a mixture of ethyl alcohol, an alcoholthickening agent and a radiopaque substance into the globus pallidus.

Description

limited tates l atent THERAPEUTIC COR [POSITIONS AND METHOD FOR TREATING PARKINSONISM John Clarke Saunders, Orangeburg, N.Y., and Jack Lazarus, Jersey City, N.J., assignors to Ciba Pharma ceutical Products Inc., Summit, N.J., a corporation of New Jefsey N Drawing. Application May 8, 1957 Serial N0. 657,708
17 Claims. (Cl. 16765) This invention relates to compositions and methodsfor the treatment of paralysis agitans.
Paralysis agitans, commonly known as Parkinsons disease, is a degenerative process of that part of the brain known as the basal ganglia. The cause of the degeneration is unknown but the symptoms are readily detectable. Among the more apparent of these is a perculiar tremor and rigidity of either or both of the upper extremities. Although slow in onset, the tremors gradually become more and more noticeable, particularly when an attempt is made to write. As the disease progresses, the tremor and rigidity may become so profound that they completely incapacitate the afflicted individual.
Although Parkinsonism is, to date, an incurable disease, it is common practice to give at least symptomatic relief. This is usually done by means of drug therapy, surgery or a combination of both. Atropine, scopolamine, stramonium, trihexyphenidyl hydrochloride and similar palliatives have been used in the past but patients rapidly develop tolerances to these drugs and staggering of medications often becomes necessary. Since the disease is chronic, a point is eventually reached where drug administration becomes completely ineifective; Procaine injections are sometimes successful, but they too are temporary.
Attempts to obtain symptomatic relief from tremor and rigidity surgically have included removal of the basal ganglia, section of the pyramidal tract in the spinal cord and similar techniques. Tying off the anterior choroidal artery, which supplies blood to the globuspallidus and related pyramidal nuclei has also been attempted but it has proven to be dangerous since it causes loss or disease of the ganglion cells of the basal ganglia. Another disadvantage of this technique is the variability of the origin and distribution of the anterior choroidal artery, making it difficult for the neurosurgeon to coagulate and destroy it.
From a surgical point of view the target area for the relief of symptoms of Parkinsonism appears to be the globus pallidus, which is a small portion of the basal ganglia and which, when diseased, is contributory to the development of Parkinsonian tremor and rigidity. The destruction of this neurological center, if effected properly without acc mpanying obliteration of immediately adjacent vital areas, has been thought of as the best means for affording symptomatic relief. One of the methods heretofore employed for this purpose has been to inject a quantity of dehydrated alcohol directly into the globus pallidus preceded by an injection of procaine to confirm the location of the needle in the desired position. One of the more apparent disadvantages of this technique is that the alcohol frequently spreads to other vital areas, thus not only precluding the formation of a discrete lesion, but frequently causing extremely serious results such as hemiplegia or death.
We have now found that a composition comprising a mixture of ethyl alcohol and an alcohol-soluble thickening agent is useful for chemosurgical removal of Parkinsonian symptoms. The novel composition completely overcomes the disadvantages'of dehydrated alcohol per se. When injected properly into the globus .pallidus it becomes localized in this area resulting in the formation of a permanent, discrete lesion, which abolishes Parkinsonian tremors and rigidity without'loss of'motorpowers'. It will be noted that the addition of an alcohol-soluble thickening agent to ethyl alcohol not only localizes the effect of the alcohol after injection, thus insuring proper concentration in the globus pallidus, but also prevents the dissemination of the alcohol into the internal capsule, thus precluding fatal results.
A wide variety of alcohol-soluble thickening agents may be used in accordance with this invention, the only precaution being that the thickcners must be non-toxic and suitable for parenteral administration. Among those which we have found desirable for this purpose are various' celluloses such as ethyl cellulose, cellulose acetate phthalate, etc.; the higher fatty alcohols such as cetyl alcohol, stearyl alcohol; palmityl alcohol, and their corresponding acids; alcohol-soluble silicone resins, synthetic resins, gums, etc. Castor oil, which is one of the few fixed alcohol-soluble oils, can also be used. We prefer to use ethyl cellulose.
The amount of alcohol-soluble thickening agent to be combined with the ethyl alcohol is critical not only from the physiological point of-view, i.e. compatibility with tissue, but also because ofthe practical problems involved. Since an 18-gauge needle is usually employed for administration, the viscosity of the composition must be such as to permit easy flow through the bore of a needle of such diameter. Thus, if too much thickening agent is added to the alcohol, the mixture will not pass through the needle. If, on the other hand, an inadequate amount is added to the alcohol, the spread of the alcohol will not be impeded and attendant serious results may occur. We have found that a solution containing from about 0.5% to about 50% of thickening agent is suitable, the exact amount used depending largely upon the kind of thickener being employed. For example, if ethyl cellulose is used, a preferred range is from about 5% to about 20%. Optimally, we have found that'a concentration of from about 8% to about 10% ethyl cellulose affords the most desirable results. If cetyl alcohol is used as the thickening agent, it may be added in an amount varying from about 20% to about 40%. A preferred range is from about 25% to about 35%.
It is to be noted that although we have'described the applicability of the compositions of this invention to Parkinsonism, this is not to be construed as an intent to limit their use for this specific purpose. On the contrary, the compositions may be used for the relief of symptoms in a wide variety of hyperkinetic diseases such as psychomotor equivalents, Huntingtons chorea, athetosis, cerebral palsy, etc. and it is intended that the use or uses in the treatment of these diseases be included within the scope of'this invention.
The exact dose ofthe composition to be administered will vary somewhat from patient to patient depending upon the condition of the patient, the extent of the disease being treated and the desires of the administering surgeon. In general, a dose within the range of 0.4 ml. to 1.0 ml. may be administered directly into the globus pallidus. In practice it has been found that an. initial dose of about 0.4 ml. followed by a second dose within the above range about three days postoperatively is adequate for removing symptoms of Parkinsonian tremor and rigidity.
If desired, a small quantity of X-ray contrast material, for example an alcohol-soluble, iodinated, organic radiopaque substance suitable for parenteral administration, may be added to the composition for the purpose of enabling the surgeon to determine not only the exact location, but also the extent of the discrete lesion. An amount varying from about 1% to about 20%, preferably is adequate for this purpose. A wide variety of substances may be used, representative examples of which are the following: 3-acetamido-2,4,6-triiodobenzoic acid; ethyl iodophenylundecylate; ethyl ester of the iodinated mixture of oleic and linoleic acids of poppy seed oil (available under the trademark Ethiodol); ethyl diiodobrassidate; N,Nadipyl-bis-(3-amino-2,4,6-triiodo) benzoic acid; 3,5-diiodo-4-pyridone-N-acetic acid; fi-(3-amino- 2,4,6-triiodophenyl)-a-ethylpropionic acid; and l-methyl- 3,5-diiodo-4-pyridone 2,6-dicarbocyelic acid.
The method of preparation of the compositions is not critical. It involves admixing the desired quantities of alcohol and thickening agent thoroughly to insure complete solution (with heat if necessary) and sterilizing the resulting mixture at the proper temperature and pressure.
This is a continuation-in-part of our copending application Serial No. 587,225, filed May 25, 1956, and now abandoned.
The following examples are intended to illustrate the invention, but not to limit its scope:
Example 1 Ethyl cellulose, 20 cps. viscosity 8.0 Ethyl alcohol, 95% qs 100.0
Example 2 Cetyl alcohol 30.0 Ethyl alcohol, 95% qs 100.0
For preparation, follow directions given in Example 1.
Example 3 Ethyl cellulose, 20 cps. viscosity 10.0 Ethyl iodophenylundecylate 10.0
Ethyl alcohol, 95% qs 100.0
Dissolve the ethyl cellulose and the ethyl iodophenylundecylate in 85 ml. ethyl alcohol and mix until dissolved. Add suflicient quantity ethyl alcohol to bring the volume to 100 ml. Filter and sterilize under 10 lbs. steam pressure at 115 C. for 30 minutes.
What is claimed is:
. 1. A therapeutic composition comprising a mixture of ethyl alcohol, from about 0.5% to about 50% of an alcohol-thickening agent and a radiopaque substance.
2. A therapeutic composition comprising a mixture of ethyl alcohol, from about 0.5% to about 50% of an alcohol thickening agent and from about 1% to about 20% of a radiopaque substance.
3. A therapeutic composition comprising essentially a mixture of ethyl alcohol and from about 0.5% to about 50% cetyl alcohol.
4. A therapeutic composition comprising essentially a mixture of ethyl alcohol and from about 0.5% to about 50% stearyl alcohol.
5. A therapeutic composition comprising essentially a mixture of ethyl alcohol and from about 0.5% to about 50% stearic acid.
6. A therapeutic composition comprising essentially a mixture of ethyl alcohol and from about 0.5 to about 50% cellulose acetate phthalate.
7. A therapeutic composition comprising essentially a mixture of ethyl alcohol and from about 5% to about 20% ethyl cellulose.
8. A therapeutic composition comprising essentially a mixture of ethyl alcohol and irom about 8% to about 10% ethyl cellulose.
9. A therapeutic composition comprising a mixture of ethyl alcohol, from about 0.5% to about 50% of an alcohol-thickening agent and from about 1% to about 20% ethyl iodophenylundecylate.
10. A therapeutic composition comprising a mixture of ethyl alcohol, from about 0.5% to about 50% ethyl cellulose and from about 1% to about 20% ethyl idophenylundecylate.
11. A therapeutic composition comprising a mixture of ethyl alcohol, from about 0.5 to about 50% of an alcohol-thickening agent and from about 1% to about 20% ethyl diiodobrassidate.
12. A therapeutic composition comprising a mixture of ethyl alcohol, from about 0.5 to about 50% of an alcohol-thickening agent and from about 1% to about 20% of the ethyl ester iodinated mixture of oleic and linoleic acids of poppy seed oil.
13. A therapeutic composition comprising a mixture of ethyl alcohol, from about 0.5% to about 50% of an alcohol-thickening agent and from about 1% to about 20% N,N-adipyl-bis-(3-amino-2,4,6-triiodo) benzoic acid.
14. A therapeutic composition comprising a mixture of ethyl alcohol, from about 0.5 to about 50% of an alcohol-thickening agent and from about 1% to about 20% 3,5-diiodo-4-pyridone-N-acetic acid.
15. A method for the treatment of Parkinsonism which comprises injecting a mixture of ethyl alcohol and an alcohol-thickening agent into the globus pallidus.
16. A method for the treatment of hyperkinetic dis cases which comprises injecting into the body a mixture of ethyl alcohol, an alcohol-thickening agent and a radiopaque substance.
17. A method for the treatment of Parkinsonism which comprise injecting a mixture of ethyl alcohol, an alcoholthickening agent and a radiopaque substance into the globus pallidus.
References Cited in the file of this patent UNITED STATES PATENTS 2,155,658 Hermann et al. Apr. 25, 1939 2,196,768 Hiatt Apr. 9, 1940 2,572,828 Archer Oct. 30, 1951 2,698,807 Asaii Jan. 4, 1955 2,704,270 Olsson Mar. 15, 1955 OTHER REFERENCES

Claims (1)

17. A METHOD FOR THE TREATMENT OF PARKINSONIUM WHICH COMPRISE INJECTING A MIXTURE OF ETHYL ALCOHOL, AN ALCOHOLTHICKENING AGENT AND A RADIOPAQUE SUBSTANCE INTO THE GLOBUS PALLIDUS.
US657708A 1957-05-08 1957-05-08 Therapeutic compositions and method for treating parkinsonism Expired - Lifetime US2903396A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US657708A US2903396A (en) 1957-05-08 1957-05-08 Therapeutic compositions and method for treating parkinsonism

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US657708A US2903396A (en) 1957-05-08 1957-05-08 Therapeutic compositions and method for treating parkinsonism

Publications (1)

Publication Number Publication Date
US2903396A true US2903396A (en) 1959-09-08

Family

ID=24638339

Family Applications (1)

Application Number Title Priority Date Filing Date
US657708A Expired - Lifetime US2903396A (en) 1957-05-08 1957-05-08 Therapeutic compositions and method for treating parkinsonism

Country Status (1)

Country Link
US (1) US2903396A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2983750A (en) * 1959-07-03 1961-05-09 Bristol Myers Co Tris methylammonium salicylate salts
WO1987005214A1 (en) * 1986-03-06 1987-09-11 New York University Method for blocking calcium channels
US4897426A (en) * 1986-03-06 1990-01-30 New York University Method for blocking calcium channels
US20070116647A1 (en) * 2002-05-07 2007-05-24 Jacques Theron Medicinal preparation particularly for the treatment of slipped discs hernias

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2155658A (en) * 1936-01-08 1939-04-25 Chemische Forschungs Gmbh Surgical and medical preparations
US2196768A (en) * 1938-03-11 1940-04-09 Eastman Kodak Co Enteric coating
US2572828A (en) * 1947-11-24 1951-10-30 Sterling Drug Inc Alkoxyalkyl esters of monoiodomono-alkoxybenzoic acids
US2698807A (en) * 1951-01-10 1955-01-04 Callaghan Hession Corp Coating compositions containing ethyl cellulose and a process of making the same
US2704270A (en) * 1951-04-16 1955-03-15 Leo Ab Antihistaminic injectable X-ray contrast media

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2155658A (en) * 1936-01-08 1939-04-25 Chemische Forschungs Gmbh Surgical and medical preparations
US2196768A (en) * 1938-03-11 1940-04-09 Eastman Kodak Co Enteric coating
US2572828A (en) * 1947-11-24 1951-10-30 Sterling Drug Inc Alkoxyalkyl esters of monoiodomono-alkoxybenzoic acids
US2698807A (en) * 1951-01-10 1955-01-04 Callaghan Hession Corp Coating compositions containing ethyl cellulose and a process of making the same
US2704270A (en) * 1951-04-16 1955-03-15 Leo Ab Antihistaminic injectable X-ray contrast media

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2983750A (en) * 1959-07-03 1961-05-09 Bristol Myers Co Tris methylammonium salicylate salts
WO1987005214A1 (en) * 1986-03-06 1987-09-11 New York University Method for blocking calcium channels
JPS63500525A (en) * 1986-03-06 1988-02-25 ニュ−ヨ−ク　ユニバ−シィティ Methods for blocking calcium channels
US4897426A (en) * 1986-03-06 1990-01-30 New York University Method for blocking calcium channels
US20070116647A1 (en) * 2002-05-07 2007-05-24 Jacques Theron Medicinal preparation particularly for the treatment of slipped discs hernias
US20100329991A1 (en) * 2002-05-07 2010-12-30 Jacques Theron Medicinal preparation particularly for the treatment of slipped discs hernias
US8153696B2 (en) * 2002-05-07 2012-04-10 Jaques Theron Medicinal preparation particularly for the treatment of slipped discs hernias

Similar Documents

Publication Publication Date Title
RU2270003C2 (en) Paclitaxel-base medicinal agent stabilized with albumin for treatment of solid tumor
DE3927113C2 (en) Agent for the treatment of severe pain conditions and process for their preparation
RU2095060C1 (en) Composition showing analgetic or antiinflammatory activity, a method of analgia or treatment of allergic diseases
DE2158226A1 (en) MEDICINAL INGREDIENTS CARRIER MADE OF SILICONE RUBBER
Cotton et al. Anticonvulsant effects of magnesium sulfate on hippocampal seizures: therapeutic implications in preeclampsia-eclampsia
KR19990037094A (en) Pharmaceutical composition with controlled rate of drug release
Driessen et al. Clinical effects of regional intravenous Guanethidine (Ismelin®) in reflex sympathetic dystrophy
Langerman et al. Prolongation of epidural anesthesia using a lipid drug carrier with procaine, lidocaine, and tetracaine
Aldrete et al. Reverse carotid blood flow—a possible explanation for some reactions to local anesthetics
Burn et al. Fall of blood pressure after a noradrenaline infusion and its treatment by pressor agents
US2903396A (en) Therapeutic compositions and method for treating parkinsonism
JPH064534B2 (en) Combination drug for long-term pain relief
Madden et al. Efficacy of LY233053, a competitive glutamate antagonist, in experimental central nervous system ischemia
US2518510A (en) Stable injectable oil-pectin therapeutic compositions
Rossi et al. Intracranial gangliogliomas
CN115944635A (en) Application of aminothiazole derivative in preparing medicine for treating immune inflammation
CN1244403A (en) Preparation of isotomic Shengmei injecta
Kadzielawa et al. Electroencephalographic analysis of the central action of dihydroxyphenylalanine
KR20230050084A (en) Drug delivery system comprising polylactic-co-glycolic acid and beta-cyclodextrin containing drug
Wiranowska et al. A mouse model for the study of blood-brain barrier permeability
Wahlberg et al. Polymeric controlled-release amsacrine chemotherapy in an experimental glioma model
CN116751201A (en) Compound or composition and application thereof in preparing anesthetic
AU2013282753B2 (en) Injectable supersaturated acetaminophen solution for spinal administration
Hirsch Xylocain Anaesthesia in Lumbar Myelography with Water Soluble Iodine Contrast
CN117085112A (en) Ziconotide for needleless injection and preparation method thereof